Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure. Key assessments include glomerular filtration rate, tubular function, renal plasma flow, urine output, mean arterial pressure, and various biomarkers. The trial is expected to enroll 27 heart failure patients.

"We are delighted that dosing has begun in this important Phase Ib study of CD-NP in patients with heart failure," said Peter Strumph, Chief Executive Officer of Nile. "This Mayo sponsored study, which is the fourth clinical study of CD-NP, will enable us to continue to build on our understanding of the clinical effects of CD-NP."

Results from Nile's Phase Ia study in 22 healthy volunteers were consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, preserved renal function, increased natriuresis and diuresis with minimal effect on mean arterial pressure.

In parallel with Mayo's Phase Ib study, Nile is currently dosing Phase Ib and Phase IIa studies of CD-NP in heart failure patients. The primary objective of the Phase Ib study is to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of CD-NP in pati
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... CHAPEL HILL, N.C. , Aug. 22, 2014 /PRNewswire/ ... pharmaceutical organizations and thought leaders in the healthcare sector. ... to evolve, the iPad is changing how Medical Science ... MSLs are using the tablet to ... physicians but also to better coordinate thought leader interactions ...
(Date:8/22/2014)... 2014 ... announced the addition of the  "Global Laboratory ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... for any modern science laboratory as it ... It can be broadly classified into two ...
(Date:8/22/2014)... 22, 2014 Research ... addition of the  "Global Operating Room Equipment ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating ... environment in a healthcare facility used to ... technically advanced equipment, which ensures patient care ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 The ... - Trends & Forecasts to 2018” defines and ... and forecasting of the global revenue and consumption. ... the global polycarbonate resin market with analysis of ... is segmented, and consumption and revenues are forecasted ...
(Date:8/23/2014)... York, New York (PRWEB) August 23, 2014 ... stemming from the 2012 GranuFlo and NaturaLyte dialysis ... multidistrict litigation underway in U.S. District Court, District ... an updated docket report issued by the U.S. ... 15th, at least 2,028 claims are pending in ...
(Date:8/23/2014)... August 23, 2014 Peripheral intervention surgeries ... remove plaques, etc, thereby addressing the root cause of ... of blood to the other part of the arteries ... blood. These procedures require the use of a catheter, ... and polymers), these catheters are inserted through a thin ...
(Date:8/23/2014)... According to the new research report, "Electronic ... - Regional Trends & Forecast to 2019," defines ... analysis and forecast of value individually. Along with ... by applications and geography are also discussed in ... and 26 figures spread through 234 pages and ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 Having been ... and dental hygienist from Arlington, Texas, saw a need for ... and toothpaste. "That’s when I came up with the idea ... No-Brush provides an effective way for a user to clean ... need to carry multiple items. It also helps avoid plaque ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3
... Medarex, Inc.,(Nasdaq: MEDX ) is scheduled to host ... Annual Meeting of the American Society of Clinical,Oncology (ASCO) ... at 8:00 a.m. Eastern Time / 7:00 a.m. Central ... be joined by Jedd D. Wolchok, M.D.,Ph.D., Director of ...
... Children Not Meeting Daily Physical,Activity Recommendations, INDIANAPOLIS, ... care homes are unlikely to be meeting physical ... released today,at the 55th Annual Meeting of the ... operated family child care homes, as the second,largest ...
... KV Expects Filings To Be Completed Within Automatic Form 10-K Extension ... ... ST. LOUIS, May 30 KV Pharmaceutical Company,(NYSE: KVa/KVb), a ... products and generic/non-branded prescription pharmaceuticals,announced today that it expects to complete ...
... new University of,Detroit Mercy School of Dentistry and Clinic ... from 9 a.m. to 1 p.m. on the new ... screenings for community,members, as well as oral health awareness ... of the School of Dentistry,s 75th,Anniversary., Over 211,000 ...
... 2008, New YorkThe number of uninsured young adults in the ... 13.3 million in 2005making the 19-to-29 age group one of ... insurance. According to a newly updated report from The Commonwealth ... attend college and 34 percent of college graduates will spend ...
... of Michigan,ranked among the nation,s top 30 hospitals ... America,s Best Children,s Hospitals. This publication,ranked each pediatric ... neonatal care, neurology and neurosurgery, respiratory,disorders, and general ... neurology and neurosurgery., U.S. News uses several ...
Cached Medicine News:Health News:Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO 2Health News:Preschoolers in Family Child Care Homes Need More Activity 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 2Health News:KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings 3Health News:UDM School of Dentistry to Host Community Open House 2Health News:Young adults at risk: 13.7 million lack health insurance coverage 2Health News:Young adults at risk: 13.7 million lack health insurance coverage 3Health News:DMC Children's Hospital of Michigan Ranked Among America's Best 2
Fluoroperm 151 lens meets special needs of certain patients who need exceptional oxygen permeability for specific corneal condition or lifestyle requirements....
... Thinsite is designed using sophisticated lathing ... concepts. Thinsite lenses feature a center thickness ... ranges. While all plus powered Thinsite lenses ... over standard designs. The unique design eliminates ...
An easy-to-fit RGP daily wear lens with a unique bi-aspheric back surface design that provides excellent patient comfort and adaptation. Boston Envision contact lenses are an ideal alternative for vi...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
Medicine Products: